Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIM-CRC3: Radiotherapy, Penpulimab, and Fruquintinib in Advanced Colorectal Cancer
NCT07904130Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Oct 2026
- Primary completion
- Oct 2028
01
Overview
A Phase 2 trial of penpulimab, fruquintinib in colorectal cancer (CRC), sponsored by West China Hospital of Sichuan University. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
penpulimabfruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07904130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07904130.